Stock SYNTA PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Synta Pharmaceuticals Corp. Share Price Nasdaq

Equities

US87162T2069

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Synta Pharmaceuticals Corp.
19/05 Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
19/05 Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI

Financials

Sales 2024 * 75.76M 6.29B Sales 2025 * 361M 29.99B Capitalization 4.89B 406B
Net income 2024 * -583M -48.41B Net income 2025 * -403M -33.47B EV / Sales 2024 * 55.4 x
Net cash position 2024 * 694M 57.59B Net cash position 2025 * 292M 24.23B EV / Sales 2025 * 12.7 x
P/E ratio 2024 *
-8.1 x
P/E ratio 2025 *
-12.6 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.63%
More Fundamentals * Assessed data

Latest news about Synta Pharmaceuticals Corp.

Certain Common Stock of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Pre Funded Warrants of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Performance Stock Units of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Restricted Stock Units of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Certain Options of Madrigal Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. CI
Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing MT
B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating MT
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating MT
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday MT
Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell MT
Transcript : Madrigal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
Madrigal Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT
More news

Latest transcript on Synta Pharmaceuticals Corp.

Logo Synta Pharmaceuticals Corp.
Madrigal Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024
More transcripts

Analyst Recommendations on Synta Pharmaceuticals Corp.

Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing MT
B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating MT
UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating MT
BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective MT
BofA Securities Starts Madrigal Pharmaceuticals With Underperform Rating, $150 Price Target MT
More recommendations

Press releases Synta Pharmaceuticals Corp.

Madrigal: Q1 Earnings Snapshot AQ
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates AQ
Nonalcoholic Steatohepatitis Market to Observe Impressive Growth During the Forecast Period | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Eli Lilly and Company, Madrigal Pharmaceuticals AQ
Madrigal Statement on the Passing of Dr. Stephen Harrison AQ
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 AQ
More press releases

News in other languages on Synta Pharmaceuticals Corp.

EE.UU. - Valores a seguir en Wall Street (actualizado)
Madrigal Pharmaceuticals : Super Micro Computer, Madrigal, Tencent... les valeurs à suivre aujourd'hui à Wall Street -
Madrigal Pharmaceuticals : lève 600 millions de dollars pour le lancement de son Rezdiffra
Wall Street ouvre en baisse, les regards tournés vers la Fed
EE.UU. - Valores a seguir en Wall Street (actualizado)
More news

Managers and Directors - Synta Pharmaceuticals Corp.

Managers TitleAgeSince
Edward Chiang FOU
 Founder - 01/11/01
William Sibold CEO
 Chief Executive Officer - 08/23/08
Rebecca Taub FOU
 Founder 71 01/16/01
Members of the board TitleAgeSince
Fred Craves FOU
 Founder 78 01/11/01
Julian Baker CHM
 Chairman 57 15/23/15
Ken Bate BRD
 Director/Board Member 73 22/16/22
More insiders

Company Profile

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Sector
Biotechnology & Medical Research
Calendar
06/08/2024 - Q2 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+12.30% 118B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.15% 106B
BIONTECH SE Stock BioNTech SE
-8.14% 23.4B
ARGENX SE Stock argenx SE
-1.69% 21.78B
GENMAB A/S Stock Genmab A/S
-10.60% 18.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.25% 16.72B
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.33% 15.97B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.80% 14.03B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.03% 11.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MDGL Stock
  4. Stock